Updated:
Indiana Hemophilia and Thrombosis Center
Shapiro and Greist founded the Indiana Hemophilia and Thrombosis Center (IHTC) in 1998 under the parent entity Innovative Hematology, Inc. The center operates...
Indiana Hemophilia and Thrombosis Center
Shapiro and Greist founded the Indiana Hemophilia and Thrombosis Center (IHTC) in 1998 under the parent entity Innovative Hematology, Inc. The center operates as Indiana's sole federally designated hemophilia treatment center, a structural monopoly that routes rare-disease patients, clinical research contracts, and pharmaceutical partnerships through a single care network. IHTC treats hemophilia, thrombosis, von Willebrand disease, HHT, and sickle cell disease, serving as a Center of Excellence recognized for patient care, education, and clinical research. IHTC's economic model fuses fee-for-service clinical revenue with pharmaceutical-sponsored trial income. The center runs a dedicated Gene Therapy Hub in Indianapolis, hosting industry trials for novel hemophilia gene therapies. Its institutional partner network includes the Indiana University School of Medicine, which provides long-standing clinical training support and financial backing. The Hemophilia Alliance and the American Thrombosis and Hemostasis Network (ATHN) integrate IHTC into national drug-purchasing coalitions and outcomes-research infrastructure that amplify its negotiating position with drug manufacturers. The organization maintains its clinical headquarters at 8326 Naab Road in Indianapolis, operates the Gene Therapy Hub, and lists participation in the Indiana technology network TechPoint — a signal of digitizing care delivery or data infrastructure investments. Eddie Williams, a senior global life sciences executive, serves on the board of Innovative Hematology, Inc. Effective April 2026, Sanjay P. Ahuja assumed the combined role of CEO and Medical Director, marking a formal succession from the founding clinical leadership team. IHTC is not structured as a traditional grantmaking foundation or pooled endowment. It operates as a clinical operating company with an asset-owner balance sheet — a hybrid that generates recurring revenue from patient encounters and pharmaceutical contracts while building long-term capital. That architecture makes it a rare entity in institutional portfolios: a healthcare provider whose investment reserves sit inside an operating nonprofit, governed by a board with pharmaceutical and life-sciences expertise rather than endowment-consultant orthodoxy.
General information
Firm type
Endowment / Foundation
Year founded
1998
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
8326 Naab Road, Indianapolis, IN 46260, United States
Additional offices
Indianapolis, IN (Gene Therapy Hub)
Principals
Sanjay P. Ahuja
Chief Executive Officer & Medical Director
Amy Shapiro
Co-Founder, Co-Medical Director
Anne Greist
Co-Founder, Co-Medical Director
Eddie Williams
Board Member, Innovative Hematology, Inc.
Sector focus
Frequently asked questions
How is the Indiana Hemophilia and Thrombosis Center structured as an asset owner?
IHTC sits inside the nonprofit parent Innovative Hematology, Inc., not as a standalone grantmaking foundation. Its balance sheet builds from clinical operating revenue — patient visits, pharmaceutical-sponsored trial contracts — rather than a single family's liquidity event. This structure creates an endowment-like pool of capital governed by a board with deep pharmaceutical and life-sciences expertise.
What role does IHTC play in the hemophilia gene-therapy market?
IHTC operates a dedicated Gene Therapy Hub in Indianapolis that runs clinical trials for novel hemophilia gene therapies. As one of the largest federally recognized hemophilia treatment centers in the U.S., it provides pharmaceutical companies with access to a concentrated rare-disease patient population, making it an active economic participant in the drug-development value chain.
Who controls capital allocation decisions at IHTC?
Governance flows through the board of Innovative Hematology, Inc., which includes senior global life sciences executive Eddie Williams. As of April 2026, Sanjay P. Ahuja serves as CEO & Medical Director, succeeding co-founders Amy Shapiro and Anne Greist in the top management role. This dual clinical-executive office holds substantial influence over the balance-sheet strategy.
Does IHTC invest directly in pharmaceutical or healthcare companies?
IHTC is not a known direct investor in portfolio companies. Its economic ties to the pharmaceutical sector come through clinical research contracts and trial-site revenue, not equity stakes. The institution's reserves grow from operating surpluses generated by those contracts, but any external investment portfolio remains undisclosed.
What gives IHTC durable sourcing advantage in rare-disease care and research?
As Indiana's sole federally hemophilia treatment center, IHTC captures nearly all regional bleeding-disorder patients through a referral monopoly. That concentrated patient base makes the center a priority trial site for drug developers, locking in recurring pharmaceutical revenue and federal designation benefits that a multi-site competitor could not easily replicate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: